Loading company…
Austin-based biotechnology company developing SL-325, an antibody for inflammatory autoimmune disorders such as IBD.
Founded in 2016 in Austin, US, Shattuck Labs, Inc. develops biologic therapeutics led by SL-325, a monoclonal antibody antagonist of Death Receptor 3 (DR3) for chronic inflammatory conditions including Inflammatory Bowel Disease. Josiah Hornblower is CEO and co-founder. The company raised USD 201.99 mn in an IPO on December 21, 2023, and has completed 5 deals. In fiscal 2024 it reported revenue of USD 5.72 mn and EBITDA of -USD 74.59 mn.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in